Please assess the completion status of the following clinical trial:

Trial Title: Efficacy & Safety Study of Oral Aripiprazole in Adolescents With Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with a current DSM-IV-TR diagnosis of schizophrenia, and a history of the illness (diagnosis or symptoms) for at least 6 months prior to screening.~* Subjects who have shown previous response to antipsychotic treatment (other than clozapine) and are not resistant to treatment with other antipsychotics.~* Subjects who are currently being treated with oral or depot antipsychotics other than clozapine.~* Subjects with a history of relapse and/or exacerbation of symptoms when they are not receiving antipsychotic treatment.~Exclusion Criteria:~* Subjects with a current DSM-IV-TR diagnosis other than schizophrenia.~* Subjects with delirium, dementia, amnesia or other cognitive disorders; subjects with psychotic symptoms that are better accounted for by another general medical condition(s) or direct effect of a substance (i.e., medication, illicit drug use, etc.).~* Subjects with attention deficit disorder or attention deficit hyperactivity disorder and/or subjects who were on a stimulant treatment for any period of time over the last one year prior to screening.~* Subjects with any neurodevelopmental disorder, except Tourette's syndrome.~* Subjects experiencing acute depressive symptoms within the past 30 days prior to screening.~* Subjects who meet the DSM-IV-TR criteria for substance dependence (including alcohol and benzodiazepines, but excluding caffeine and nicotine) within the past 180 days prior to screening.~* Subjects who have epilepsy, a history of seizures (except for a single childhood febrile seizure or post-traumatic seizure), or a history of severe head trauma or stroke, or have a history or current evidence of other unstable medical conditions.~* Subjects with a history of subclinical hypothyroidism (TSH ≥ 4.0 mIU/L), known hypothyroidism or hyperthyroidism (unless the condition has been stabilized with medication for at least 90 days prior to entry into Phase 1 or Phase 2).~* Subjects who have a medical history of uncontrolled diabetes, labile or unstable diabetes (brittle diabetes), newly diagnosed diabetes, or clinically significant abnormal blood glucose levels.

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Phase 1 (Type: EXPERIMENTAL): Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
- Phase 2 (Type: EXPERIMENTAL): Aripiprazole (2-mg, 5-mg, 10-mg, 15-mg, 20-mg, 25-mg or 30-mg)
- Phase 3 (Type: PLACEBO_COMPARATOR): Aripiprazole (10-mg, 15-mg, 20-mg, 25-mg or 30-mg) or placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).